
    
      This is a open label, single-arm multicenter phase Ib study,and is designed to evaluate
      Objective Response Rate (ORR) in advanced esophageal squamous cell carcinoma progressed
      following treatment with taxane/platinum/fluorouracil treated with anti-EGFR monoclonal
      antibody SCT200.
    
  